Boston Scientific announces 4-year data for Rezūm BPH treatment

Posted in Medical Device

January 28, 2019 • 2 min read

Boston Scientific (NYSE: BSX) recently announced that data from a randomized clinical trial demonstrate that Rezūm Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment...

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Colorectal Cancer Syndrome

Posted in Future of Healthcare

January 24, 2019 • 2 min read

23andMe today received FDA clearance for a genetic health risk report on a hereditary colorectal cancer syndrome. The clearance follows the FDA’s authorization for 23andMe’s BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in March 2018. The MUTYH-Associated Polyposis report was submitted to the FDA using the 510(k) submission pathway, enabled by the BRCA decision in March 2018...